Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. immune disease
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Magazines
Downloads
Videos

Refine by
Date

  • Older

Immune Disease Articles & Analysis: Older

43 news found

Mastering Tissue Dissociation - Episode 4: The Spleen

Mastering Tissue Dissociation - Episode 4: The Spleen

This precise dissociation is pivotal for advancing studies on immune response and related disease mechanisms. Read the application note EPISODE 1: THE HEART EPISODE 2: THE LUNG EPISODE 3: THE LIVER ...

ByBertin Technologies


Ace Therapeutics Accelerates Preclinical GI and Hepatology Research with Disease Model Customization Services

Ace Therapeutics Accelerates Preclinical GI and Hepatology Research with Disease Model Customization Services

Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...

ByAce Therapeutics


Ace Therapeutics Announces Vaccine Development Services Against Superbugs

Ace Therapeutics Announces Vaccine Development Services Against Superbugs

Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...

ByAce Therapeutics


CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service

CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service

HLA regions are associated with the greatest number of human diseases in the human genome, and HLA typing is particularly important for assessing immune compatibility between organ donor and recipient pairs. ...

ByCD Genomics


Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

“We look forward to combining our product development expertise with the capabilities of AFRIMS in chikungunya epidemiology and field studies, and of our academic partners in infectious disease modeling and efficacy trial design, to find ways to address chikungunya disease, a public health threat for which no vaccine or treatment ...

ByCBRNe World - Falcon Communications UK


Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. However, despite the remarkable impact of FDA-approved biologics based on secreted proteins such as insulin, human growth hormone, and erythropoietin, this class of biologics ...

ByJuvena Therapeutics, inc.


Oxford Brain Diagnostics’ grey matter quality measure selected as secondary outcome for Alzheimer’s Phase 2 clinical trial

Oxford Brain Diagnostics’ grey matter quality measure selected as secondary outcome for Alzheimer’s Phase 2 clinical trial

The trial will use CDM® technology to assess the efficacy of XPro™ compared with placebo on grey matter integrity in patients with mild AD. The role of the immune system and inflammation in Alzheimer’s disease has been broadly known for years but it is becoming increasingly clear that effective management of AD may require anti-inflammatory ...

ByOxford Brain Diagnostics Ltd.


CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic

CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic

The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims more lives than any cancer. Infectious disease testing (including sepsis) is one of the fastest growing molecular diagnostic segments ...

BySepset Biosciences Inc.


Neovii and Fosun Pharma Enter into an Exclusive Agreement

Neovii and Fosun Pharma Enter into an Exclusive Agreement

Further, the Agreement entails clinical development to expand Grafalon’s regulatory approval in China to the prevention of Graft versus Host Disease following allogenic stem cell transplantation (“SCT”), so as to align its approved usages in China with those in Europe and other countries worldwide. Additional objective is to evolve Grafalon’s usages from ...

ByNeovii Pharmaceuticals AG


Creative Proteomics Cytokine Boosts Your Research and Discovery with Mouse Cytokine Assay

Creative Proteomics Cytokine Boosts Your Research and Discovery with Mouse Cytokine Assay

Cytokine assays can determine the immune function of the body and are important for diagnosis, disease course observation, efficacy determination, and treatment monitoring. ...

ByCreative Proteomics


Enterome to present promising clinical progress on its OncoMimics™ pipeline and Mimicry Platform at Jefferies Healthcare Conference

Enterome to present promising clinical progress on its OncoMimics™ pipeline and Mimicry Platform at Jefferies Healthcare Conference

Belichard will provide an overview of the progress the Company has made with its advanced OncoMimics™ pipeline, including its first-in-class off-the-shelf therapeutic cancer vaccine, EO2401, as well as its other fully owned EndoMimics™ pipeline for immune diseases using its Mimicry drug discovery platform. ...

ByEnterome


Cipla enters partnership to provide affordable oncology biosimilars to South Africa

Cipla enters partnership to provide affordable oncology biosimilars to South Africa

In 2018, Cipla paved the way for more affordable treatments in the fight against dreaded diseases with the launch of the first biosimilar drug, Filgrastim Teva, for oncology and haematology patients in South Africa. Cipla also recently launched a biosimilar for the treatment of immune-mediated inflammatory disease. According to the Cancer ...

BymAbxience


CD Genomics MicrobioSeq Releases Microbial Transcriptomics for Disease Research and Drug Development

CD Genomics MicrobioSeq Releases Microbial Transcriptomics for Disease Research and Drug Development

Microbial transcriptome and metatranscriptomic information is important for predicting resistance to specific antibiotics, understanding host-pathogen immune interactions, quantifying gene expression changes, and tracking disease progression. ...

ByCD Genomics


Cytovale IntelliSep Test Demonstrates Potential to Rapidly Risk-Stratify Suspected COVID-19 Patients in New Study

Cytovale IntelliSep Test Demonstrates Potential to Rapidly Risk-Stratify Suspected COVID-19 Patients in New Study

Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, today announced a new study on its investigational IntelliSep test has been published in the peer-reviewed journal PLOS ONE. ...

ByCytovale Inc.


Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis

Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis

Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial ...

ByCytovale Inc.


Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

“Sanofi’s collaboration with Exscientia aims to transform how we discover and develop new small molecule medicines for cancer and immune-mediated diseases. Application of sophisticated AI and machine learning methods will not only shorten drug discovery timelines, but will also help to design higher quality and better targeted medicines for ...

ByExscientia


Leadership change and even more momentum: Biotech pioneer Neovii under new management

Leadership change and even more momentum: Biotech pioneer Neovii under new management

It is also indicated for prevention after stem cell transplantation to protect against graft-versus-host disease (GVHD). Since its development, the pharmaceutical has been continuously refined in line with medical progress and for the benefit of patients. ...

ByNeovii Pharmaceuticals AG


EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial

Our technology offers maximum flexibility as multiple relevant drug substances, including biologics and other innovative compounds, can be incorporated into the film, making our drug delivery platform suitable for several clinical indications, including Barrett’s disease and reflux disease, two areas of high unmet medical need.” “Eosinophilic ...

ByEsoCap AG


New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

“The amlitelimab data presented at EADV support our belief that OX40-Ligand has the potential to provide a novel approach to treating a range of immune-mediated diseases," said Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation at Sanofi. ...

ByKiadis Pharma NV


Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

Results describing the biology and candidate selection of VE202 were previously published in Science and Nature (multiple). About Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is a debilitating, life-long condition that results from chronic inflammation of the intestinal tract. ...

ByVedanta Biosciences, Inc

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT